This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Study Type
OBSERVATIONAL
Enrollment
490
patients with treatment naive or R/R CLL who treatment with Zanubrutinib
Peking University People's Hospital
Beijing, Beijing Municipality, China
Progression Free Survival (PFS)
PFS is defined as the duration from date of Zanubrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause
Time frame: up to two years
Overall Survival
OS is defined as the time from the starting date of Zanubrutinib to the date of death due to any cause.
Time frame: up to two years
Time to Next Therapy (TTNT)
The TTNT will be calculated as the difference between Zanubrutinib initiation date and initiation date of the first next therapy for CLL
Time frame: up to two years
Adverse Events
Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations
Time frame: up to two years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.